Immunotherapies in phase II and III trials for the treatment of systemic lupus erythematosus. (2nd January 2017)

• Record Type: Journal Article
• Authors: Radin, Massimo; Cecchi, Irene; Schreiber, Karen; Baldovino, Simone; Rossi, Daniela; Menegatti, Elisa; Roccatello, Dario; Sciascia, Savino
• Is Part Of: Expert opinion on orphan drugs. Volume 5:Number 1(2017:Jan.)
• Page Start: 55
• Page End: 69
• Publication Date: 2017-01-02
• Subjects: Systemic lupus erythematosus -- biological -- therapy -- autoimmunity; Orphan drugs -- Periodicals; Rare diseases -- Periodicals; Chemotherapy -- Periodicals; 615.1
• DOI: 10.1080/21678707.2017.1257937
• Languages: English
• ISSNs: 2167-8707

Abstract

ABSTRACT: Introduction : Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by highly heterogeneous clinical manifestations and a multi systemic involvement. SLE is prone to relapses and remissions, which makes the management challenging. Moreover, conventional therapies may have considerable side-effects, which highlights the demand for new therapeutic strategies. The progress towards a better understanding of the underlying pathogenesis has led to the development of biological therapies targeted directly against crucial molecular mediators of SLE. Areas covered : In this review we analyzed available biological therapies, phase II and III trials and upcoming new therapies that are currently under development for SLE treatment. Expert opinion : The complex pathogenesis of SLE is far from being fully understood. Evidence towards a better understanding of the pathogenic pathways, the cellular and molecular mediators involved in SLE are emerging. Henceforth, new biological therapeutic options targeting crucial molecular mediators involved in the pathogenesis of SLE are being developed. In the future, the management of SLE could profit from the use of biological therapies that are tailored towards the individual patient's specific clinical manifestations, taking into account their genetic background and pathogenic fingerprint.